JP2022538908A5 - - Google Patents

Info

Publication number
JP2022538908A5
JP2022538908A5 JP2022500008A JP2022500008A JP2022538908A5 JP 2022538908 A5 JP2022538908 A5 JP 2022538908A5 JP 2022500008 A JP2022500008 A JP 2022500008A JP 2022500008 A JP2022500008 A JP 2022500008A JP 2022538908 A5 JP2022538908 A5 JP 2022538908A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
cdr1
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022500008A
Other languages
English (en)
Japanese (ja)
Other versions
JP7709636B2 (ja
JP2022538908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/040711 external-priority patent/WO2021003399A1/en
Publication of JP2022538908A publication Critical patent/JP2022538908A/ja
Publication of JP2022538908A5 publication Critical patent/JP2022538908A5/ja
Application granted granted Critical
Publication of JP7709636B2 publication Critical patent/JP7709636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500008A 2019-07-03 2020-07-02 抗組織因子抗体－薬物コンジュゲート及び関連方法 Active JP7709636B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03
US62/870,644 2019-07-03
PCT/US2020/040711 WO2021003399A1 (en) 2019-07-03 2020-07-02 Anti-tissue factor antibody-drug conjugates and related methods

Publications (3)

Publication Number Publication Date
JP2022538908A JP2022538908A (ja) 2022-09-06
JP2022538908A5 true JP2022538908A5 (enExample) 2023-07-10
JP7709636B2 JP7709636B2 (ja) 2025-07-17

Family

ID=74100836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500008A Active JP7709636B2 (ja) 2019-07-03 2020-07-02 抗組織因子抗体－薬物コンジュゲート及び関連方法

Country Status (21)

Country Link
US (1) US20220257789A1 (enExample)
EP (1) EP3994150A4 (enExample)
JP (1) JP7709636B2 (enExample)
KR (1) KR20220029724A (enExample)
CN (1) CN114222752B (enExample)
AR (1) AR119346A1 (enExample)
AU (1) AU2020299398C9 (enExample)
BR (1) BR112021025720A2 (enExample)
CA (1) CA3141428A1 (enExample)
CL (2) CL2021003414A1 (enExample)
CO (1) CO2022001083A2 (enExample)
CR (1) CR20220047A (enExample)
DO (1) DOP2021000268A (enExample)
EA (1) EA202193309A1 (enExample)
EC (1) ECSP22007981A (enExample)
IL (1) IL289138A (enExample)
MX (1) MX2021015974A (enExample)
PE (1) PE20221004A1 (enExample)
PH (1) PH12021553289A1 (enExample)
TW (1) TWI879780B (enExample)
WO (1) WO2021003399A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
TW202342517A (zh) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 使用抗組織因子抗體之炎性疾病治療
JP2025508779A (ja) * 2022-02-24 2025-04-10 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 抗体及びその薬物コンジュゲート並びに用途
WO2023172951A1 (en) * 2022-03-09 2023-09-14 Exelixis, Inc. Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
US20250276077A1 (en) * 2022-04-05 2025-09-04 Immunome, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
CN121039165A (zh) * 2023-04-28 2025-11-28 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
ES2905569T3 (es) * 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
EA202090741A1 (ru) 2017-11-02 2020-07-30 Генмаб А/С Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
TWI841554B (zh) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
EP4171652A1 (en) * 2020-06-29 2023-05-03 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2022538908A5 (enExample)
US20230381321A1 (en) Camptothecin conjugates
US11834498B2 (en) Biparatopic FR-alpha antibodies and immunoconjugates
JP6412114B2 (ja) 抗体薬物コンジュゲート
JP2024096335A (ja) 親水性抗体－薬物コンジュゲート
ES2895623T3 (es) Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes
CN106938051B (zh) 靶向于组织因子的抗体-药物偶联物
DK3102606T3 (en) ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES
JP2022530524A5 (enExample)
TW202203978A (zh) 電荷可變連接子
KR20170054430A (ko) 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
JP7203729B2 (ja) ベンゾジアゼピン誘導体の選択的スルホン化
CA2982522A1 (en) Site-specific antibody-drug conjugates
JP2024530368A5 (enExample)
CN106999606A (zh) 抗体药物偶联物
CN111295201A (zh) 抗egfr抗体药物结合物（adc）和其用途
AU2017344198A1 (en) Medical use of anti-c met antibody-cytotoxic drug conjugate
US20200297863A1 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
CN115052663A (zh) Alk5抑制剂缀合物及其用途
JP2026505738A (ja) 抗体－薬物複合体及びその使用
RU2832083C2 (ru) Бипаратопные fr-альфа антитела и иммуноконъюгаты
RU2021130453A (ru) Бипаратопные fr-альфа антитела и иммуноконъюгаты